Overview
A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD
Status:
Unknown status
Unknown status
Trial end date:
1969-12-31
1969-12-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to explore the safety and efficacy of Macugen given as maintenance therapy in patients who have had initial success with another AMD treatment. Patients must have 1, but not more than 3 prior treatments for Neovascular AMD.Phase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Eyetech PharmaceuticalsCollaborator:
Pfizer
Criteria
Inclusion Criteria:- Subfoveal CNV secondary to AMD
- At least 1 but not more than 3 prior treatments for AMD
Exclusion Criteria:
- Subfoveal scar or subfoveal atrophy
- Significant media opacities, including cataract, which might interfere with visual
acuity